Monograph Details
|
|
Poisoning & Drug Dependence
> Poisoning/overdose
|
|
KAYEXALATE |
| Manufacturer |
|
Sanofi Aventis |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Cation exchange resin. |
| Generic Name |
|
Sodium polystyrene sulfonate; pwd; sodium content 4.1mEq/g. |
| Indications |
|
Hyperkalemia. |
| Children |
|
See literature. Use 1g per 1mEq of potassium as basis of calculation. |
| Adults |
|
See literature. Oral: 15g 1–4 times daily, as a susp. Rectal enema: 30–50g in 100mL every 6 hrs. |
| Contraindications |
|
Hypokalemia. Concomitant magnesium hydroxide. Obstructive bowel disease. Neonates. |
| Precautions |
|
Hypokalemia. Monitor electrolytes, ECG. Hypernatremia. CHF. Hypertension. Edema. Constipation. Monitor for colonic necrosis (esp. in children). Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Avoid non-adsorbable cation donating antacids and laxatives (e.g., aluminum hydroxide). Sorbitol may cause colonic necrosis (concomitant use not recommended). Digoxin toxicity potentiated by hypokalemia. Reduces absorption of thyroxine, lithium. |
| Adverse Reactions |
|
GI irritation/ulceration/necrosis, sodium retention, hypokalemia, hypocalcemia, fecal impaction. |
| How Supplied |
|
Jar (453g)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
